Paliperidone NDC 27241-276

NDC codes

FDA NDC Directory

Product NDC (as listed)27241-276Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27241-0276Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27241-276-30	27241027630	30 TABLET, EXTENDED RELEASE in 1 BOTTLE (27241-276-30)Marketed from Jun 26, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Paliperidone
Generic name (nonproprietary): paliperidone
Active ingredients: Paliperidone — 1.5 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Ajanta Pharma USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 218514
Marketing start: Jun 26, 2024
Listing expires: Dec 31, 2027
Identifiers: Product ID 27241-276_77fecc29-f36d-450b-a808-aca3ba89a186SPL ID 77fecc29-f36d-450b-a808-aca3ba89a186SPL set ID 71985eb4-07df-41c9-8b9a-85f39e92b7d0RxCUI 672567, 672569, 672571, 866103UNII 838F01T721UPC 0327241277306, 0327241276309, 0327241279300, 0327241278303
Pharmacologic class: Atypical Antipsychotic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427241027630 followed by a unit qualifier and the quantity

Package 27241-0276-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 11, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1.1 ) Adults: Efficacy was established in three 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. ( 14.1 ) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. ( 1.2 ) Efficacy was established in two 6-week trials in adult patients. ( 14.2 ) 1.1 Schizophrenia Paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see Clinical Studies ( 14.1 )]. The efficacy of paliperidone extended-release tablets in schizophr…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 218514

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 218514
Product	Strength	Form · route	Labeler	Product NDC
Paliperidone	Paliperidone 3 mg/1	Tablet, Extended releaseOral	Ajanta Pharma USA Inc.	27241-277
Paliperidone	Paliperidone 6 mg/1	Tablet, Extended releaseOral	Ajanta Pharma USA Inc.	27241-278
Paliperidone	Paliperidone 9 mg/1	Tablet, Extended releaseOral	Ajanta Pharma USA Inc.	27241-279